



To: UPHS Physicians and Staff

From: **Julianne Qualtieri, MD, Medical Director- Flow Cytometry, Division of Hematopathology**
Joshua Edwards, MBA, Technical Manager- Hematopathology

Date: September 30, 2021

Re: **CLL MRD by Flow Cytometry In House Testing**

The Flow Cytometry Laboratory at HUP has evaluated and validated an assay to assess Minimal Residual Disease (MRD) for Chronic Lymphocytic Leukemia (CLL) by Flow Cytometry. This is a replacement test for the current send-out testing being performed at Mayo Laboratories. Our in-house test evaluates approximately 500,000 CD45+ cellular events with an established sensitivity of 0.01%.

Please continue using the same order in Penn Chart for CLL MRD by Flow Cytometry [Px Code: CLLMRD], and follow the same process of sending the peripheral blood specimen to the Laboratory. All orders placed starting Thursday, September 30th 2021 will automatically route to this new testing. For details about specimen collection, transport, and result interpretation, refer to the Laboratory Test Services Guide, available through the Penn Medicine Intranet.

If you need any further clarification of this testing change, please contact Joshua Edwards, Manager of the Flow Cytometry Laboratory, for assistance at either joshua.edwards@pennmedicine.upenn.edu or 267-319-5622.